Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)

Program Status

Recruiting

Phase

Phase 1

Prior Immunotherapy Allowed

No

CRC-directed Trial

Yes

Drugs

Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, Yervoy

Tags

MSS/ MMRp

Comments

Prof. Niels Halama is Principal Investigator. This is a trial “with Maraviroc”, a continuation of the the MARACON trial and of PICCASSO trial (NCT03274804). See Helpful Links.

NCT ID

LUMINESCENCE

Date Trial Added

2019-01-25

Updated Date

2019-07-16